St Vincents Private Hospitals

Biography

Professor Hang Quach is a leading haematologist who subspecialises in multiple myeloma. She is Professor of Haematology at the University of Melbourne and serves as the Departmental Head of Clinical Haematology and Clinical Haematology Research at St Vincent’s Hospital Melbourne.

Prof Quach’s career is distinguished by her strong commitment to clinical and translational research, with a focus on novel therapies for blood cancers. Her work aims not only to expand treatment options for patients but also to ensure access to cutting-edge therapies that might otherwise be unavailable to Australians. Her translational research specifically explores myeloma immunology and the tumour microenvironment.

Through competitive grants, industry partnerships, and philanthropy, Prof Quach has secured more than $16 million in research funding for myeloma as of January 2025. She is widely published in the field and is recognised internationally for her contributions to multiple myeloma research.

In addition to her clinical and research leadership roles at St Vincent’s, she serves as Co-Chair of the Myeloma Working Party of the Australasian Leukaemia and Lymphoma Group (ALLG), Deputy Chair of the Myeloma Scientific Advisory Group (MSAG) for Myeloma Australia, where she leads the development and biennial update of the Australian National Treatment Guidelines for Multiple Myeloma, Steering Committee Member of the Australian Myeloma Research Consortium (AMaRC).

Prof Quach is deeply committed to advancing the standard of care for patients with blood cancers, not only through clinical innovation and research, but also through her leadership roles in national and international medical organisations and professional bodies.

Educational Videos featuring Professor Quach
Click on the links below to watch:

• PODCAST: Blood Cancer Talks
• Educational Video 1
• Educational Video 2
• Educational Video 3
• Phase Ib/II trial of sonrotoclax + dexamethasone in RR-MM harboring T(11;14) (VJHemOnc)
• Educational Video 4
• Educational Video 5
• Management of ocular events in patients treated with belantamab mafodotin plus pom/dex in DREAMM-8 (VJHemOnc)
• The challenges with treating RR-MM in resource-restricted regions (VJHemOnc)